STCube

STCube Current Assets

The Current Assets of STCube (052020.KQ) as of Oct 24, 2026 is 1.08 B KRW. In the previous year, Current Assets was 95.97 B KRW — a change of -98.88% (lower).

Current Assets

1.08 BKRW

YoY

-98.88%

Last updated:

Current Assets of STCube is 2025 1.08 B KRW. Current Assets of STCube was 2024 95.97 B KRW. It decreases by -98.88% lower compared to the previous year.

The STCube Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
47.16 B KRW
Jan 1, 2019
46.95 B KRW
Jan 1, 2020
2.65 B KRW
Jan 1, 2021
21.73 B KRW
Jan 1, 2022
55.99 B KRW
Jan 1, 2023
38.34 B KRW
Jan 1, 2024
95.97 B KRW
Jan 1, 2025
1.08 B KRW
The STCube Current Assets history
YEARCurrent AssetsYoY
1.08 BKRW-98.88%
95.97 BKRW+150.32%
38.34 BKRW-31.53%
55.99 BKRW+157.68%
21.73 BKRW+719.63%
2.65 BKRW-94.35%
46.95 BKRW-0.45%
47.16 BKRW+233.50%
14.14 BKRW-42.87%
24.75 BKRW+118.52%
11.33 BKRW+253.94%
3.20 BKRW-50.33%
6.44 BKRW+42.45%
4.52 BKRW-13.47%
5.23 BKRW-18.79%
6.44 BKRW+47.41%
4.37 BKRW-60.43%
11.03 BKRW+33.33%
8.27 BKRW+114.41%
3.86 BKRW-30.68%
5.57 BKRW-5.92%
5.92 BKRW-16.04%
7.05 BKRW+36.02%
5.18 BKRW-4.73%
5.44 BKRW+47.53%
3.69 BKRW+7.65%
3.42 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Current Assets of STCube is 1.08 B KRW in 2025.

Current Assets of STCube changed from 95.97 B KRW to 1.08 B KRW, representing a -98.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets STCube since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — STCube

All Key Metrics — STCube